Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: May 31, 2007
Business Overview: Neogen develops, manufactures, and markets products for food safety (diagnostic test kits for pathogens, toxins, and allergens) and animal safety (pharmaceuticals, rodenticides, vaccines, and veterinary instruments). The company operates two primary segments: Food Safety and Animal Safety.
Key Financial Metrics
| Metric | Fiscal 2007 | Fiscal 2006 | Fiscal 2005 |
|---|---|---|---|
| Net Sales | $86,138,000 | $72,433,000 | $62,756,000 |
| Gross Margin | $44,563,000 (51.7%) | $37,006,000 (51.1%) | $30,603,000 (48.8%) |
| Operating Income | $13,504,000 (15.7%) | $10,805,000 (14.9%) | $7,452,000 (11.9%) |
| Net Income | $9,125,000 | $7,029,000 | $4,929,000 |
| Diluted EPS | $0.97 | $0.83 | $0.59 |
| Cash and Equivalents | $13,424,000 | $1,959,000 | $1,972,000 |
| Working Capital | $41,060,000 | $26,252,000 | $22,644,000 |
| Long-Term Debt | $0 | $9,955,000 | $0 |
Segment Revenue Mix (2007): Food Safety (54.5%); Animal Safety (45.5%).
International Sales: 38.0% of total revenue.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% to $86.1 million, driven by a 34% increase in Food Safety sales and a 5% increase in Animal Safety sales.
- Profitability: Net income rose 30% to $9.1 million. Gross margins improved by 60 basis points to 51.7% due to product mix changes and operational efficiencies.
- Liquidity: Cash and cash equivalents surged from $1.96 million to $13.42 million. This was primarily due to a $12.2 million net proceeds from a common stock offering in June 2006 and the full repayment of $9.955 million in long-term debt during fiscal 2007.
- Acquisitions: Significant revenue contributions came from the December 2005 acquisition of UCB's dairy antibiotic testing business and the February 2006 acquisition of Centrus International Inc.
Guidance, Outlook, and Risks
Management Commentary: Management does not provide specific financial forecasts. The company expects to maintain R&D expenditures at 4% to 6% of total revenues. Future growth strategies include new product introductions, expanding international sales, and strategic acquisitions.
Risks and Contingencies:
- Acquisition Integration: Success depends on effectively integrating acquired businesses; failure could materially affect results.
- Intellectual Property: The company relies on patents and trade secrets; infringement litigation or failure to secure licenses could disrupt operations.
- Regulatory Environment: Products are subject to regulation by the USDA, EPA, and FDA. Changes in regulations could impact costs or revenues.
- Market Volatility: Results are subject to fluctuations due to the agricultural market cycle, weather conditions, and competitive pricing pressures.
- Foreign Operations: International sales (38% of revenue) expose the company to currency fluctuations and foreign regulatory changes.
Investor Verification Checklist
- Stock Split: Verify the impact of the 3-for-2 stock split approved on July 26, 2007, which was not reflected in the fiscal 2007 financial statements.
- Customer Concentration: Confirm that no single customer exceeds 10% of revenue, except for one Food Safety distributor at 11.8%.
- Debt Status: Verify the company remains debt-free with a $10 million unused revolving credit line available.
- Acquisition Synergies: Monitor the integration progress of the UCB and Centrus acquisitions to ensure projected revenue and margin benefits are realized.
- Regulatory Approvals: Track the status of regulatory approvals for key products like BotVax B, EqStim, and ImmunoRegulin.